Lynparza Blazes PARP Trail In China
Executive Summary
AstraZeneca/Merck & Co’s Lynparza has become the first PARP inhibitor to be approved in China, continuing a recent trend of accelerated reviews and approvals for novel therapies from multinationals in the country.
You may also be interested in...
China Vs. Cancer: Seven Companies Given Price Cuts, Roche Gets New Approval
Cancer drug prices again on the chopping board in China, including for some products already affected, and more are coming.
China Calling: Dozens Of Drug Firms Handpicked For Fast Track Reviews
Four dozen innovative new drugs are slated to be reviewed under China's fast-track system, including more than 20 products for rare diseases.
Cancer, Orphan, Pediatric Drug Developers Join China Foreign Data Acceptance Party
China officially issues regulation accepting clinical data obtained from overseas studies, with a priority on treatments for critical, rare and pediatric conditions.